Trial
NCT06963346
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
AstraZeneca
Condition
Bladder Cancer
Intervention
Romidepsin
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-09